Symvess off the shelf vessel approved for rapid vascular injury response, Humacyte unveils

Symvess off the shelf vessel approved for rapid vascular injury response, Humacyte unveils
Humacyte launches FDA approved Symvess

Humacyte has introduced Symvess, a ready-to-use, human-derived, bioengineered vessel designed for the treatment of extremity vascular injuries. Symvess is described as the first and only FDA approved acellular tissue engineered vessel available for off the shelf emergency use.

The product aims to streamline vascular repair by providing instant access to a tissue engineered option, eliminating the need for operating room preparation or donor harvesting. According to Humacyte, Symvess may accelerate response times and reduce complications in trauma and vascular emergency settings.

Humacyte has recently secured at least $1.475 million in Symvess vessel sales to support a clinical program in Saudi Arabia, according to a company announcement. The firm has also filed for regulatory approval of Symvess in Israel, aiming to expand options for urgent arterial repair in the region, according to a previous statement. These moves reflect Humacyte’s efforts to broaden the clinical adoption of its bioengineered vascular technology internationally.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.